Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Artiva Biotherapeutics, Inc. Common Stock(ARTV)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ARTV
09/24/2026: ARTV (1-star) is currently NOT-A-BUY. Pass it for now.
Artiva Biotherapeutics is a clinical-stage biotechnology company developing off-the-shelf NK cell therapies to treat cancer and autoimmune diseases. Its primary strength lies in a proprietary, scalable manufacturing platform aimed at increasing patient access to cell-based treatments. The main growth story hinges on the clinical success of its lead candidate, AB-101. However, the company faces significant risks, including early-stage pipeline uncertainty, high capital requirements, and intense competition from major pharmaceutical firms. The stock is best suited for growth-oriented investors who can tolerate high volatility and recognize that long-term value depends entirely on successful clinical milestones and potential future commercialization.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company offers high-risk, high-reward exposure to the emerging field of allogeneic cell therapy. |
| Momentum investor | Mixed fit | Momentum is highly dependent on positive clinical data readouts and sector sentiment. |
| Value investor | Weak fit | The lack of commercial products and current operating losses make this unsuitable for traditional value metrics. |
| Dividend investor | Weak fit | The company does not pay dividends and requires all cash for R&D operations. |
| Low-risk investor | Weak fit | The inherent volatility of clinical-stage biotech poses significant risk to capital. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage biotech stocks often experience sharp price swings based on trial results and regulatory news. |
| Valuation risk | High | Valuations are highly speculative as they depend on future potential success rather than current earnings. |
| Competition risk (Cell Therapy) | Medium / high | Competition from large, well-capitalized firms could limit the commercial potential of ARTVs therapies. |
| Business quality | Medium | As a pre-revenue company, business quality is defined by the strength of the R&D pipeline and execution capability. |
| Dividend income | Low / none | Investors should expect no dividend income for the foreseeable future. |
| Execution risk | High | Successfully navigating clinical trials and regulatory approval processes is complex and uncertain. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 4.13% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/24/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 366.19M USD | Price to earnings Ratio - | 1Y Target Price 35.8 |
Price to earnings Ratio - | 1Y Target Price 35.8 | ||
Volume (30-day avg) 396.5K shares | Beta 2.2 | 52 Weeks Range 2.71 - 14.53 | Updated Date 09/24/2026 |
52 Weeks Range 2.71 - 14.53 | Updated Date 09/24/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.23 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Cell Therapy R&D | Clinical development of AB-101 and other pipeline candidates. | The company does not currently have commercial products; value is derived from future drug development success. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 37.40M | Price to Sales(TTM) 8.11 |
Enterprise Value 37.40M | Price to Sales(TTM) 8.11 | ||
Enterprise Value to Revenue 7.54 | Enterprise Value to EBITDA - | Shares Outstanding 48.89M | Shares Floating 19.43M |
Shares Outstanding 48.89M | Shares Floating 19.43M | ||
Percent Insiders 15.31 | Percent Institutions 84.16 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Artiva Biotherapeutics, Inc. Common Stock
Exchange NASDAQ | Headquarters San Diego, CA, United States | ||
IPO Launch date 2024-07-19 | CEO, Principal Financial & Accounting Officer and Director Dr. Fred Aslan M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 115 | Website https://www.artivabio.com |
Full time employees 115 | Website https://www.artivabio.com | ||
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. The company also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.